Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 196

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 196
---
 statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis.The following table presents the fair value of financial assets as of December 31, 2024 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$277,760 $277,760 $— $— $277,760 Marketable investments580 580 559 — 21 Warrant assets4,366 4,366 — — 4,366 Foreign currency forward contract2,475 2,475 — — 2,475 

63

The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$274,504 $274,504 $— $— $274,504 Marketable investments48 48 — — 48 Warrant assets1,759 1,759 — — 1,759 Foreign currency forward contract974 974 — — 974 Financial liabilitiesContingent consideration payable$4,900 $4,900 $— $— $4,900 

Note 12. Revenue Recognition

As of December 31, 2024, Enteris (Pharmaceutical Development Segment) is classified as held for sale. The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.The following table provides the contract revenue recognized by revenue source for the years ended December 31, 2024 and 2023 (in thousands):December 31,20242023Pharmaceutical Development SegmentLicense Agreement$49 $273 Pharmaceutical development and other3,567 931 Total contract revenue$3,616 $1,204 The Company’s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied.The Company’s contract liabilities are presented as deferred income as of  December 31, 2024 in the consolidated balance sheets (in thousands